Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors

Immune checkpoint inhibitors (ICI) induce adverse events (irAEs) that do not respond to steroids, i.e. steroid-refractory (sr) irAEs, and irAEs in which steroids cannot be tapered, i.e. steroid-dependent (sd) irAEs, in about 10% of cases. An evidence-based analysis of the effectiveness of second-line immunosuppressive agents with regard to irAE and tumor control is lacking.

Source: European Journal of Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Theresa Ruf, Rafaela Kramer, Andrea Forschner, Ulrike Leiter, Friedegund Meier, Lydia Reinhardt, Pia D ücker, Carolin Ertl, Dirk Tomsitz, Julia K. Tietze, Ralf Gutzmer, Evelyn Dabrowski, Lisa Zimmer, Anja Gesierich, Sarah Zierold, Lars E. French, Thomas Tags: Original Research Source Type: research